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DipalmitoylphosphatidylcholineThis work presents a thorough investigation of the interaction of the novel synthetic pyrrolidinone analog
MMK3 with the model membrane system of dipalmitoylphosphatidylcholine (DPPC) and the receptor active
site. MMK3 has been designed to exert antihypertensive activity by functioning as an antagonist of the
angiotensin II receptor of subtype 1 (AT1). Its low energy conformers were characterized by 2D rotating-frame
Overhauser effect spectroscopy (ROESY) in combination withmolecular dynamics (MD) simulations. Docking
study of MMK3 shows that it ﬁts to the AT1 receptor as SARTANs, however, its biological activity appears to be
lower. Thus, differential scanning calorimetry (DSC), Raman spectroscopy and small angle X-ray scattering
(SAXS) experiments on the interaction of MMK3with DPPC bilayers were carried out and results demonstrate
that the drug is well incorporated into the membrane leaﬂets and furthermore causes partial bilayer
interdigitation, although less effective than SARTANs. Thus, it appears that the nature of the bilayer matrix and
the stereoelectronic active site requirements of the receptor are responsible for the low bioactivity of MMK3.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The renin angiotensin system (RAS) constitutes the major system
that regulates blood pressure. Therefore, it is the main target in the
drug design for developing novel synthetic antihypertensive drugs.
The ﬁrst rationale behind the synthesis of novel angiotensin analogs
was to block the formation of vasoconstrictive hormone angiotensin II
(Ang II). Renin and angiotensin converting enzymes are responsible
for transforming in the body angiotensinogen to angiotensin I (Ang I)
and subsequently to Ang II. The blocking of angiotensin converting
enzyme was crowned with success and the market experienced
captopril and its congeners as beneﬁcial molecules in blood
regulation. However, their side effects of dry mouth and angioedema
precluded them from being the ideal drugs for hypertension. Recently,
the synthetic molecule aliskiren entered the market with trade named at the Institute of Biophysics
e, 8042 Graz, Austria. Tel.: +39
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ll rights reserved.Tekturna (Novartis) and is the only available inhibitor from the renin
inhibitor class [1].
The second class of synthetic molecules aims to block Ang II at the
AT1 receptor [2]. The ﬁrst peptide analogs synthesized for this purpose,
althoughnot successful, providedmolecularmodels for further rational
drug design. To comprehend the stereoelectronic requirements for
receptor binding, the stereochemical features of Ang II and its peptide
antagonists sarmesin and sarilesin were explored [3–12]. These
synthetic peptide analogues and other non-peptide AT1 antagonists
(commercially available and novel compounds) are designed to mimic
the C-terminal part of Ang II. In this regard, losartan was the ﬁrst
successful peptidomimetic analog to be marketed. Furthermore,
angiotensin receptor blockers (ARBs) have been developed to produce
amore complete blockade of the action of angiotensin II as compared to
other drug classes as well as decrease of their side effects [13–18].
Based on the molecular characteristics of these antagonists, a new
avenuewas explored in an attempt to design and synthesize novel AT1
antagonists. Thus, (5S)-1-benzyl-5-(1H-imidazol-1-yl-methyl)-2-
pyrrolidinone) denoted as MMK1 was synthesized to possess
pyrrolidinone as template instead of biphenyltetrazole. However,
MMK1 did not show the desired biological properties as the in vitro
and in vivo studies demonstrated [19]. For this purpose, we proceeded
with the synthesis of a derivative of MMK1, the (5S)-1-benzyl-5-(1H-
423C. Fotakis et al. / Biochimica et Biophysica Acta 1798 (2010) 422–432benzimidazol-1-yl-methyl)-2-pyrrolidinone named MMK3 (Fig. 1),
which differs from MMK1 in two aspects: (a) it has a methoxy group
at 11 position and (b) it contains a benzimidazole ring instead of a
imidazole ring. The rationale behind these structural modiﬁcations
was ﬁrst to mimic in part the Ang II antagonist sarmesin (Sar) and
second to extend the aromaticity of the molecule. We note, that the
key requirement for antagonist activity of sarmesin is its methoxy
group. In fact, the superagonist Sar[AngII] is identical to sarmesin
except that it contains a methoxy group instead of phenolic hydroxyl
group at Tyr4. Detailed synthesis of this molecule and biological data
are reported elsewhere [20]. However, MMK3 as did MMK1, appeared
not to have the desired activity both in vitro and in vivo. To some
extent this was a surprising outcome, since the initial molecular
modeling certiﬁed good binding properties of MMK3 with the active
site of the AT1 receptor [19, 20].
The cell membrane is believed to play an important role in the
cause and progression of hypertension. On the basis of extensive
studies of the antagonist losartan, our laboratory has proposed a two-
step model, in which this antihypertensive drug is ﬁrst incorporated
into the bilayers through the lipid–water interface and then laterally
diffuses to reach the active site of the AT1 receptor [21]. A two-step
mechanism has also been suggested for other amphiphilic molecules
such as cannabinoids and calcium channel antagonists [22–25]. For
the above reason it was decided to study the interaction of MMK3
with lipid model membranes.
The lowest energy conformer of MMK3 was derived from 2D
ROESY data in combination with molecular modeling. Additionally,
since new models of the AT1 receptor have been published [26], we
have re-examined the interactions of MMK3 in the receptor site, this
time in a lipid environment by applying MD simulations. Then, in a
second part, the MMK3:bilayer interactions in great detail were
characterized by analyzing differential scanning calorimetry (DSC),
Raman spectroscopy and small angle X-ray diffraction experiments.Fig. 1. Chemical structures of MMK3 and the carboxyl terminal segment of sarmesin. For MM
Equivalent aromatic rings of MMK3 and sarmesin are labeled with the same letters A–C.Hydrated DPPC lipids are used because they spontaneously form
multilamellar bilayers whose dynamic and thermotropic properties
have been extensively studied by various biophysicalmethods [27–36].
Moreover, phosphatidylcholines are themost abundant lipid species in
sarcolemma cardiac membranes. The most frequently found among
them are PCs with oleic and linoleic chains, and further DPPC [37].
Another studypoints out that partition coefﬁcient of DPPC, especially in
the ﬂuid state, resembles that of natural cardiac membranes [38].
These methodologies allows to learn about the thermodynamic
changes in the presence of MMK3, to determine chain ﬂuidity and
mobility alterations, and ﬁnally to correlate theses results with the
structural modiﬁcations on a molecular level. A concrete model for
partial bilayer interdigitation is presented and some potential scenarios
in the framework of the two-step reaction model are discussed.
2. Materials and methods
2.1. Sample preparation
MMK3 was synthesized as described previously [19,20]. Lα-
dipalmitoylphosphatidylcholine (Lα-DPPC, 99+%) was purchased
from Avanti Polar Lipids Inc (Alabaster, AL) and spectroscopic grade
CHCl3 from Sigma Aldrich (St. Louis, MO). For nuclear magnetic
resonance (NMR) measurements, the MMK3 concentration used was
10 mM dissolved in CDCl3. For DSC measurements, appropriate
amounts of DPPC and MMK3 diluted in chloroformwere mixed, dried
under stream of N2 and then stored under vacuum overnight. After
dispersing in water (50% w/w), portions of the samples (ca. 5 mg)
were sealed in stainless steel capsules obtained from Perkin-Elmer
(Norwalk, CT). The same sample preparation was carried out for the
Raman spectroscopy measurements. The amount of sample used was
ca. 40 mg. For X-ray scattering experiments aqueous dispersions of
multilamellar vesicles were prepared according to the above protocolK3 the critical dihedral angles that determine its conformational properties are deﬁned.
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tions used for the different experiments were x=0.01 (99% molar
ratio of phospholipid and 1% molar ratio of drug), x=0.05 (95%
molar ratio of phospholipid and 5% molar ratio of drug) and x=0.20
(80% molar ratio of phospholipid and 20% molar ratio of drug).
2.2. NMR spectroscopy
NMR spectra were recorded on a Varian INOVA 600 MHz
spectrometer (Palo Alto, CA) at 25 °C. The Double Quantum Filter
Correlation Spectroscopy (DQF-COSY), Heteronuclear Single Quan-
tum Coherence (1H–13C gHSQC) and Heteronuclear Multiple Bond
Correlation (1H–13C gHMBC) were performed with pulsed ﬁeld
gradients. The offset compensated Rotating Overhauser SpectroscopY
(ROESY) experiment was performed using a mixing time of 150 ms
and a 4 kHz spin-locking ﬁeld strength [39]. The 1H and 13C spectral
windows used were 6000 Hz and 30,000 Hz, respectively. The
homonuclear proton spectra were acquired with 4096 data points in
t2 dimension, 4–32 scans, 256–512 complex points in t1 dimension
and with a relaxation delay of 1–1.5 s. The 1H–13C heteronuclear
experiments were acquired with 1024–4096 data points in t2
dimension, 32–64 scans and 128–1024 complex points in t1
dimension. Experimental data were processed using Varian VNMR
software. Spectra were zero-ﬁlled two times and apodized with a
squared sine bell function shifted by π/2 in both dimensions.
Interproton distances were calculated from integrated and normal-
ized cross-peak intensities in ROESY spectra. The distance between
adjacent aromatic protons (2.46 Å) was used for calibration. The
resulted distances were corrected for the frequency offset effects to be
eliminated. Upper and lower limit constraints were estimated as
±10% of the resulted values.
2.3. Molecular mechanics (MM) conformational analysis studies
Molecular modeling analysis was performed on a Silicon Graphics
O2 workstation using QUANTA software (MSI, London, UK) and
CHARMm force ﬁeld. The dielectric constant (ɛ) was set to 1 to
simulate CDCl3 used in the NMR studies. The ﬁrst step in the
conformational analysis of MMK3 was to construct a preliminary 3D
model which was minimized using the ﬁrst order minimization
algorithms, steepest descents, conjugate gradient, and Newton
Raphson with 0.01 Kcal/(mol.A) as the convergence criterion. This
conformer was further subjected to random sampling obtaining 1000
low energy conformers. Cluster analysis led to 11 clusters using a
dihedral angle RMSD threshold criterion. The lowest energy con-
former of each cluster was further minimized. Among them, only
three conformers satisﬁed the interatomic distances measured by the
ROESY spectrum were selected.
2.4. “In silico” docking studies
Molecular docking simulations using the FlexX algorithm of SYBYL
[40] have been employed to the three lowest energy conformers of
MMK3 obtained by a combination of experimental and molecular
modeling results. FlexX uses a fast docking method that allows
ﬂexibility in the ligands, keeping the receptor rigid, and it uses an
incremental construction algorithm in order to place ﬂexible ligands
into a fully speciﬁed binding site. The default FlexX scoring function
was used in the calculations. FlexX uses formal charges, which were
turned on during docking.
2.5. Molecular dynamics (MD) simulations
MD simulations have been carried out in order to examine the
stability of ligand inside the binding pocket, and understand the
binding interactions between receptor and ligand.The coordinate of theMMK3 ligandwas submitted to PRODRG [41]
algorithm to obtain Gromacs topologies. The DPPC lipid bilayers
model for the MD simulations was taken from Karttunen [42] (it
includes a 128 DPPC lipids and 3655 water molecules coordinate ﬁle
derived from 100 ns MD simulations [43]). The MD simulations were
performed with the GROMACS 3.3.1 software package [44] using the
GROMOS96 force ﬁeld [45]. Simulations were run in the NPT
ensemble at 300 K and 1 bar with periodic boundary conditions.
During equilibration the Berendsen barostat and thermostat algo-
rithms [46] were applied. Electrostatic interactions were calculated
using the particle mesh Ewald method [47]. Cutoff distances for the
calculation of Coulomb and van der Waals interactions were 1.0 and
1.4 nm, respectively. Prior to the dynamics simulation, energy
minimization was applied to the full system without constraints
using the steepest descent integrator for 2000 steps with the initial
step size of 0.01 Å (the minimization tolerance was set to 1000 kJ/
(mol nm)). The system was then equilibrated via 250 ps simulation
with a time step of 2 fs, subsequently a 2.5 ns simulation was
performed at 300 K and 1 bar with a time step of 2 fs using the
Berendsen thermostat [46] and Parrinello–Rahman barostat algo-
rithms [48]. All bonds were constrained using the linear constraint
solver (LINCS) algorithm [49]. Visualization of the dynamics trajec-
tories was performed with the visual molecular dynamics (VMD)
software package [50] and the Origin 6.0 program (OriginLab
Corporation, Northampton, MA) was used for the plots.
2.6. Differential scanning calorimetry
Thermal scans were carried out using Perkin-Elmer DSC-7
calorimeter (Norwalk, CT). All samples were scanned from 10 to
60 °C until identical thermogramswere obtained using a scanning rate
of 2.5 °C/min. The temperature scale of the calorimeter was calibrated
using indium (Tm=156.6 °C) and DPPC bilayers (Tm=41.2 °C). The
following diagnostic parameters were used for the study of drug to
membrane interactions: Tm (maximum of the recorded heat capacity),
Tonset (the starting temperature of the phase transition) and Tm1/2 (the
half-height width of the phase transition). An empty pan for the base
line and a sample containing double distilled water were run for the
temperature range of 10–60 °C as a reference for the background. This
background was subtracted from each thermal scan of the samples.
The area under the peak, represents the enthalpy change during the
transition (ΔΗ). The mean values of ΔΗ of three identical scans were
tabulated.
2.7. Raman spectroscopy
The Raman spectra were obtained with 4 cm−1 resolution from
3500 to 400 cm−1 with interval 2 cm−1 using a Perkin-Elmer NIR FT-
spectrometer (Spectrum GX II, Norwalk, CT) equipped with CCD
detector (Norwalk, CT). The measurements were performed at a
temperature range of 27–50 °C. The laser power (a Nd:YAG at
1064 nm, Norwalk, CT) was controlled to be constant within 400 mW
during the experiments. 1500 scans were accumulated and back
scattering light was collected.
2.8. X-ray diffraction
Small angle X-ray scattering (SAXS) experiments were performed
with a small- and wide angle X-ray scattering camera with Kratky
collimation [51] (SWAXS, Hecus X-ray Systems, Graz, Austria)
mounted on a sealed-tube generator (Philips PW 1729, Philips,
Holland) operating at 2 kW. Cu-Kα radiation (λ=1.54 Å) was selected
using a tungsten ﬁlter. A linear one-dimensional position-sensitive
detector (PSD 50-M, Hecus X-ray Systems, Graz, Austria) covered the
q-range of interest from 0.004 to 0.5 Å−1. For the measurements, the
sample was transferred in a 1.5 mm capillary and measured at 25 and
Table 2
Interproton distances of ΜΜK3 as they were calculated from volumes of ROEs.
Numbering used in the table is provided in Fig. 1.
Protons Distances (Å´)
Η12–Η6 2.40
Η12–Η6′ 2.74
Η8–Η6 2.74
Η8–Η6′ 2.40
Η23–Η10 2.81
Η13–Η2 1.89
Η13′–Η2 1.89
Η13–Η3 2.57
Η13′–Η3 2.69
Η4′–Η20/21 3.00
Η13′–Η19/22 3.47
Η13–Η19/22 3.18
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as background. The exposure time was ﬁxed to one hour and at each
temperature the sample was exposed 10 times.
After background subtraction the scattering patterns were ana-
lyzed by the global analysis program (GAP) [52]. For the lattice
contributions of the lamellar ﬂuid phase the Caillé theory [53,54] and
for the gel phase the paracrystalline theory [55] were considered. For
the bilayer contribution a simple 4 parametermodel was applied. This
model uses one Gaussian for the head-groups and another for the
hydrophobic core. A more detailed description of this model is given
in Pabst's recent review [56].
3. Results
3.1. Structure assignment and conformational analysis of MMK3
2D NMR COSY, ROESY, HSQC and HMBC experiments conﬁrmed
the chemical structure of MMK3 given in Fig. 1. The 1H and 13C NMR
chemical shift assignments for 1H and 13C are given in Table 1. The
spectra of MMK3 are obtained at CDCl3 environment which has a
lipophilic nature and simulates the lipophilic environment of lipid
bilayers. Although micelle and especially liposomes are more
commonly used mediums for simulating the lipid environment [57],
our previous studies had shown that AT1 antagonists in CDCl3,
micellar or liposomal environment adopt almost identical conforma-
tions [58]. These results justify in our present study the usage of the
deuterated chloroform solvent.
Structure elucidation of MMK3 was achieved based on the
published structure of MMK1 which as mentioned in the introduction
contains the identical ring A, the methylene bridge and ring C without
methoxy group [19]. MMK3 bears benzimidazole ring instead of
imidazole ring. Brieﬂy, H15 is resonated at 7.26 ppm as a singlet like in
MMK1 [19]. Additionally, the 2D ROESY experiment allowed to
differentiate between H19/22 and H20/21, because H19/22 showed
ROE effect with H13/13′. The deshielded chemical shift values of H19/
22 relatively to H20/21 conﬁrmed the ROE results. The protons of the
methoxy group are resonating as a singlet at 3.78 ppm. The easy
assignment of primary, secondary and tertiary carbon chemical shifts
was achieved using 2D HSQC experiment and quaternary carbons
using 2D HMBC experiment. The 2D ROESY experiment showed the
through space connectivities between vicinal spatial protons pre-Table 1
Structure elucidation of MMK3. Chemical shifts obtained with 1H and 13C NMR spectra
and 1H–13C couplings through HSQC and HMBC.
Proton Chemical
shift (ppm)
Carbon Chemical
shift (ppm)
HSQC HMBC
3, 3′ 1.85 (m),
2.09 (m)
3 21.13 Η3, Η3′ Η4, Η4′, Η2, Η13, Η13′
4, 4′ 2.39 m),
2.50 (m)
4 29.73 Η4, Η4′ Η3′
2 3.63 (m) 2 55.26 Η2 Η3, Η4, Η13, Η13′, Η6
6, 6′ 3.75 (d),
4.88 (d)
6 44.47 H6, H6′ Η12, Η8
23 3.78 (s) 23 55.25 Η23
13, 13′ 3.95 (q),
4.02 (q)
13 68.91 Η13, Η13′ Η3, Η3′, Η2
12 6.68 (s) 12 113.57 Η12 Η6, Η6′, Η8, Η10
8 6.71(d) 8 120.26 H8 Η6, Η6′, Η12, Η10
10 6.80 (m) 10 113.24 Η10
9 7.20 (t) 9 130.05 Η9
19/22 7.74 (d) 19/22 127.93 Η19/22 Η20/21, Η19/22
15 7.26 (s) 15 145.33 – H19/22
20/21 7.37 (d) 20/21 130.06 Η20/21 Η20/21
17/18 132.42 – Η20/21
7 137.63 – Η6, Η6′, Η9
11 159.97 – Η23, Η12, Η10, Η9
5 175.02 – Η3, Η4, Η4′, Η2, Η6, Η6′sented in Table 2. Among the observed ROEs the critical one is that
between 4′ and protons 20/21, because it determines the bend of the
molecule and the spatial vicinity between pyrrolidinone and
benzimidazole rings. In order to determine the lowest energy
conformers, compatible with the critical ROEs, ﬁrst the molecule
was optimized using different energy minimization algorithms such
as steepest descents, conjugate gradient, and Newton Raphson until
Εi−Εi−1 was b0.001 kcal/mol. Random sampling was applied to ﬁnd
even lower energy structures using only the critical ROE H4′-Η20/21
as a constraint. The obtained different conformers were again
minimized using steepest descent and conjugate gradient algorithms
until Εi−Εi−1 was b0.001 kcal/mol and classiﬁed into clusters. Table
3 describes the average structures, deﬁned as conformers A–C of three
clusters that are compatible with the ROE constraints. In conformer A
the rings of benzimidazole and phenyl are far away from each other. In
conformer B the two rings are almost perpendicular and in close
proximity to each other. The close proximity is preserved in
conformer C, but the two rings are almost parallel. These three low
energy conformers are docked in AT1 receptor and the best scored
binding pose is shown in Fig. 2. Panel A in Fig. 2 shows the structural
details of MMK3 and the surrounding amino acids of the active site
while panel B focuses on the lipophilic proﬁle of the active site. The
major characteristic of the docking is that benzimidazole ring is
surrounded by the lipophilic moieties of Val108, Leu112 and Trp253.
The carbonyl of pyrrolidinone is hydrogen bonded with Tyr113 and
the aromatic ring C is situated between the lipophilic aromatic rings
(shown in brown color) of PHE182 and TYR113. Interestingly, the
major part of the cavity that surrounds MMK3 is lipophilic, some bear
intermediate polarity (green color). Only barely in the depth of the
cavity a small hydrophilic segment is observable (blue color).
The best-docked complex among the three lowest energy
conformers was used as input in the MD simulations using the AT1
receptor surrounded by a lipid bilayer environment. MMK3 keeps
identical conformation with that found in CDCl3 and receptor active
site at lipid bilayers environment.Table 3
Values of dihedral angles (deﬁned in Fig. 1) of low energy conformer of MMK3 and
conformers A–C. Derived conformer A has a relative value of energy−32.3, conformer
B −43.3 and conformer C −40.3 kcal/mol.
Dihedral
angles
Values
of dihedral
angles (°) for the
starting conformer
Values
of dihedral
angles (°) for
conformer A
Values
of dihedral
angles (°) for
conformer B
Values
of dihedral
angles (°) for
conformer C
τ1 101.4 77.6 85.6 −63.5
τ2 −61.9 58.7 −152.4 60.9
τ3 −67.6 −83.9 91.0 −89.3
τ4 116.0 −107.0 65.1 −175.1
τ5 173.4 5.6 −4.1 42.8
τ6 −58.5 −64.4 −59.7 −68.6
Fig. 2.Docking of MMK3 in AT1 receptor using different views. Panel A shows the structural details of MMK3 and the surrounding amino acids of the active site. Panel B focuses on the
lipophilic proﬁle of the active site. Colors of blue represent the hydrophilic, brown the lipophilic and green the intermediate polarity segments of the receptor active site.
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Fig. 3. The ligand (shown with bold sticks) at the active site of the
receptor (yellow helices) was merged to DPPC and water molecules
(shown with sticks). After the MD simulations, a conformational
analysis was performed to six rotatable bonds (deﬁned in the
corresponding Fig. 1) in ligand. The torsional angle values of these
six dihedral angles were screened throughout theMD simulations and
showed to be stable.
Fig. 4A shows the conformations of MMK3 used as input
coordinate for the ligand (derived from docking studies) before the
MD simulations and panel B of Fig. 4 the critical interactions of MMK3Fig. 3. Docking of MMK3 in AT1 receptor surrounded by lipid bilayers. Yellow color
represents the seven helices of AT1 receptor. Lipid bilayers are constituted with 128
DPPC lipids and 3655 waters.obtained after applying MD simulations. The hydrogen bonding
between the oxygen of the carbonyl ring of pyrrolidinone is now
shifted to the amide proton of GLN257. Another hydrogen bonding is
observed between the nitrogen of imidazole ring and hydrogen of
hydroxyl group of Ser109. The aromatic ring bearing the methoxy
group is surrounded by a lipophilic core (Lys199, Asn200 and Tyr184),
while the aromatic ring of benzimidazole by the amino acids Val108,
Ser109 and Phe110.
3.2. Differential scanning calorimetry
The thermal changes in the pure DPPC/water system as well as the
inﬂuenceof different concentrated inclusions ofMMK3 inDPPCbilayers
are shown in Fig. 5. Without any drug (top curve) two characteristic
endothermic peaks are visible referring to the pre- and the main
transition, respectively. The DPPC molecules form below the pre-
transition the well organized lamellar gel phase, Lβ′, while above the
main transition temperature theﬂuid lamellar phase, Lα, is apparent. An
intermediate phase, Pβ′, is also observed, in which the bilayers are
modulated by a periodic ripple (ripple phase). The recorded transition
temperatures and enthalpies are in good agreement with literature
values [27] (Table 4). In the presence of the drug MMK3 the following
observationshavebeenmade. Already, at only1mol%ofMMK3 thepre-
transition is suppressed indicating aneffect in the head-group regimeof
the drug molecule. Further, with increasing drug concentration the
main transition temperature and the transition cooperativity decrease
monotonously. This shows that drug molecules exert an additional
effect in the alkyl chains, when the concentration is increased. The
enthalpy of the main transition increases slightly from 7.5 to 8.1 kcal/
mol for x=0.01 to 0.20 and it is above that of DPPC (7.4 kcal/mol).
However, the total ΔΗ remains below the total enthalpy of the pure
DPPC bilayers (8.5 kcal/mol). As we will outline later this enthalpy
increase indicates a partial interdigitation of the alkyl chains.
3.3. Raman spectroscopy
Raman spectra of DPPC bilayers alone and in the presence of
x=0.20MMK3were obtained in a temperature range of 27–50 °C and
were recorded in a range of 500–3500 cm−1. In order to characterize
the transition behavior, especially the C–C and C–H stretching modes,
respectively, have been analyzed in greater detail.
Fig. 4. Panel A shows the conformation of MMK3 before the MD simulations and panel B the critical interactions of MMK3 obtained after applying MD simulations.
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interval reﬂects directly intramolecular trans–gauche conformational
changes within the hydrocarbon chain region of the lipid matrix.
Especially, the temperature proﬁles of the peak height intensity ratio
I1090/1130 allows the direct comparison of the bilayers disorder–order
characteristics between bilayers preparations without or with drug
incorporation [34, 35]. Fig. 6 shows the changes in I1090/1130 intensity
ratio caused by MMK3 when it is incorporated in DPPC bilayers. The
transition temperatures compare well to the results found from theFig. 5. DSC scans of DPPC bilayers containing MMK3 at molar ratios x=0.01, 0.05 and
0.20. The thermal scan attributed to DPPC bilayers shows two distinct thermal events.
The incorporation of the drug eliminates the small endothermic event (pre-transition).
The higher the incorporated concentration of the drug, the broader is the transition
width and the lower the phase transition temperature.calorimetric measurement, and it is clearly seen that MMK3 induces
lowering of the gauche/trans ratio, i.e. across the gel to ﬂuid phase
transition ΔI drops from N0.8 to about 0.2. In summary, the gel phase
region displays a greater ﬂuidity in the presence of MMK3 and on the
other side, the lipid chains in the ﬂuid chain region exhibit less trans
to gauche isomerizations.
The methylene C–H stretching mode region 2800–3100 cm−1
provides the most intense bands in the Raman spectrum of lipid
samples and is commonly used to monitor changes in the lateral
packing properties and mobility of the lipid chain in both gel and
liquid crystalline bilayer systems. In particular, the 2935/2880
intensity ratio measures effects originating from changes both in
interchain and intrachain order–disorder processes in the bilayer acyl
chains. Although the C–H stretching mode region consists of many
superimposed vibrational transitions, the peak height intensity ratio
described above provides a sensitive probe to monitor the lipid phase
transitions [59–61]. Fig. 7 shows changes in 2935/2880 peak height
intensity ratio caused by MMK3, when incorporated in DPPC bilayers.
Although the effect is not as strongly expressed as in the I1090/1130
intensity ratio, ΔI drops about 20–30% during the gel to ﬂuid phase
transition indicating that the entropy changes of the melting is
increased under the inﬂuence of MMK3.
Other characteristic band alterations give evidence for the
incorporation of MKK3 in the DPPC bilayers (data not shown). First,
an additional band around 1600 cm−1 was observed, which is
attributed to an alteration of the stretch vibration of the amide bond.
Second, at 714 cm−1 corresponding to C–N stretch vibration, a shift toTable 4
Tonset, Tm, Tm1/2 and ΔΗ of DPPC alone and with incorporated MMK3 at molar ratios
x=0.01, 0.05 and 0.20.
Samples Tonset (°C) Tm (°C) Tm1/2 (°C) ΔΗ (kcal/mol)
DPPC (32.1) 39.4 (35.9) 41.2 (2.0) 1.0 (1.12±0.07) 7.36±0.05
DPPC/MMK3
(x=0.01)
38.7 40.2 1.3 7.50±0.07
DPPC/MMK3
(x=0.05)
38.0 40.0 1.8 7.88±0.10
DPPC/MMK3
(x=0.20)
36.7 38.6 1.8 8.10±0.17
Values in brackets are given for the pre-transition of DPPC. The table refers to
experiments displayed in Fig. 5.
R data (compare also Tables 2 and 3).
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This indicates that MMK3 interacts with head-groups. Third, MMK3
caused a shift and line-shape changes at 1296 cm−1, which
correspond to stretching vibrations of the (CH)2 region of the DPPC
bilayers. This is a direct evidence of the interaction of MMK3 with
(CH)2 region of the DPPC bilayers.
3.4. X-ray diffraction
Static small angle X-ray scattering experiments were carried out
on DPPC/MKK3multilamellar vesicles to elucidate the inﬂuence of the
drug onto the model membrane system (Fig. 8). Remarkably, already
in the gel phase, MMK3 has a strong inﬂuence on the DPPC
membranes. Visible by naked eye the usually observed quasi long
range order of the membrane stacking is not preserved any more.
Instead of recording the ﬁrst ﬁve diffraction peaks as seen for pure
DPPC liposomes in the gel phase [62], only the ﬁrst order reﬂection is
relatively well expressed (Fig. 8A). The global ﬁtting analysis reveals
two reasons for the rather diffuse scattering pattern. First, the
averaged number of correlated membranes is very low, i.e. the
crystallite size is limited to only about 3 lamellae, and second, the root
mean square ﬂuctuation σ of the membranes is about 3 times higher
than normal (Table 5). The bilayer thickness as seen in the
corresponding electron density proﬁle (Fig. 8C) is only slightly
inﬂuenced by the presence of MKK3, whereas the inter-membrane
distance is about 7 Å increased when it is compared to the pure DPPC/Fig. 6. I1090/1130 vs. temperature graphs for (A) DPPC alone and (B) DPPC bilayers
containing x=0.20 of MMK3. Note, that the presence of drug lowers the phase
transition temperature and decreases ΔΙ, which is accompanied with a broadening of
phase transition temperature in agreement with DSC data (Fig. 5).
Fig. 7. Ι2935/2880 vs. temperature graphs for (A) DPPC alone and (B) DPPC bilayers
containing x=0.20 of MMK3. Note, that the presence of drug lowers the phase
transition temperature in agreement with DSC data (Fig. 5).water system (Table 5). In the ﬂuid lamellar phase at 50 °C the
diffraction pattern appears common (Fig. 8B): the quasi long range
order and the root mean square ﬂuctuation σ in the multilamellar
system are very similar to those found in pure DPPC [63–67] (Table 5).
However, the ﬁtting results show that the bilayer thickness is clearly
reduced (about −4 Å) (Fig. 8D).
4. Discussion
MMK3 is a synthetic molecule designed rationally to mimic the
antihypertensive effects of AT1 antagonists. Its lower activity
relatively to the prototype of AT1 antagonist losartan led us to study
thoroughly its conformational properties both in the receptor site and
in a lipid environment. MMK3 ﬁts nicely within the active site of the
cavity as reported for other AT1 antagonists [68]. However, it does not
tightly interact with critical amino acids of Lys199 and His256 as it is
reported with the AT1 antagonists. This may explain in part its
relatively low activity.
Since AT1 antagonists act in the active site of AT1 receptor localized
in the transmembrane segment, we postulated an important role in
their action with the membrane itself. For this reason, we have also
studied the effects of MMK3 within lipid bilayers to reveal their
possible role in the drug action.
DSC results showed that already at low concentrations (x=0.01)
MMK3 as losartan suppresses the pre-transition, a ﬁrst hint for its
polar interface activity. At higher concentrations, MMK3 causes Tm
lowering, decrease of cooperativity and slight increase of enthalpy
Fig. 8. X-ray scattering curves of DPPC/MMK3multilamellar vesicles at 25 °C (A) and 50 °C (B), and their corresponding electron density proﬁles (C), (D). (Top) The full red lines give
the global ﬁt to the data. (Bottom) dHH deﬁnes the head to head-group distance and d the lattice repeat distance. For clarity in panel D two lipidmolecule models are superimposed to
the electron density proﬁle of the bilayer. The most signiﬁcant structural parameters are summarized in Table 5.
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similar, but more pronounced, thermal effects on DPPC bilayers [69].
Tm values of DPPC bilayers containing losartan at identical concentra-
tions of x=0.05 and x=0.20 are 38.9 and 35.3 °C, respectively, and
are lower as compared to values of 40.0 and 38.6 °C observed in
bilayers containing MMK3. ΔΗ for DPPC bilayers containing x=0.05
of either MMK3 or losartan is identical, but at higher concentration of
x=0.20 ΔΗ is higher for the bilayers containing losartan. This
indicates that both drugs either signiﬁcantly increase the trans:gauche
isomerization and/or enhance the van der Waals interactions during
the main phase transition with losartan being more effective.Table 5
Structural data on pure DPPC bilayers and DPPC with 20 mol% MMK3 (x=0.20).
DPPC (20 °C) DPPC (50 °C) DPPC/MMK3
(25 °C)
DPPC/MMK3
(50 °C)
d (Å) 63.5a 67.0a 67.7 64.7
dHH (Å) 44.2a 38.3a 42 33
d−dHH (Å) 19.3a 28.7a 26 32
σ (Å) 1b 6c 3 7
a Structural data taken from the review [12].
b Estimated value from global data analysis (data not shown).
c Data concerning the root mean square ﬂuctuation in pure DPPC rely on data from
[10,11].Raman Spectroscopy results conﬁrmed and complemented those
obtained by DSC. In particular, Raman results showed that the gel
phase in the presence of MMK3 appeared more ﬂuid and the ﬂuid
phase less ﬂuid in comparison with DPPC bilayers alone. The trans:
gauche isomerization reduction points out that the enthalpy increase
observed in DSC experiments is solely attributed to the increase of van
der Waals interactions, giving a hint of partial interdigitation effect.
Again, similar but more pronounced results are obtained with DPPC
bilayers containing losartan [69].
X-ray diffraction results show that incorporated MMK3 enhances
the inter-membrane distance, d−dHH, in a range from 4 to 7 Å (see
Table 5), inducing some additional steric repulsion between
adjacent membranes. Possibly, throughout its interfacial activity it
softens the bilayer and hence causes increased undulation of the
membrane. This view is further supported by the observed increase
of the root mean square ﬂuctuation σ especially in the gel phase
(25 °C). The analysis of membrane thickness reveals a different
picture, here the main changes take place in the ﬂuid lamellar
phase, i.e. the bilayer reduces about 4 Å in the presence of MMK3. A
possible interpretation is outlined in Fig. 9. Throughout the insertion
of MMK3 into on leaﬂet of the membrane voids are induced that
need to be ﬁlled by lipids of the opposite leaﬂet. This in turn causes
neighboring lipid molecules to interdigitate partially. We note that
the scheme bases on experimental X-ray data, i.e. the decomposition
Fig. 9. Bilayer stacking in pure DPPC (left) and DPPC/MMK3multilamellar vesicles (right). The structural data are summarized in Table 5. The rough size of the MMK3 drug has been
estimated from NMR data (compare also Tables 2 and 3).
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both for the pure DPPC/water as well as for the DPPC-MMK3/water
system.
Thus, taken all complementary results of DSC, Raman spectroscopy
and X-ray diffraction together, we proved the induction of partial
interdigitation in the liquid crystalline phase for the ﬁrst time. Within
this interpretation all experimental results are consistent. First, the
enthalpy increase is caused by an increase difference of the van der
Waals interactions between gel and liquid crystalline phases. Second,
the trans:gauche isomerization reduction during the main transition
precludes the observed thinning of the ﬂuid bilayer to be due to the
effective lipid length shortening. Third, the overall thinning of the
membrane can be sufﬁciently explained by partial interdigitation as
demonstrated in Fig. 9.
We have already reported that partial interdigitation is observed
for the bulky molecule of vinblastine and the antihypertensive AT1
antagonist losartan. Both molecules are characterized as amphiphiles
that reside on the interface regime and possess net positive and
negative charges. These charges may be responsible for their stronger
anchoring in this region and cause more effective partial interdigita-
tion effect [70–72].
In conclusion, we showed that MMK3's observed lower bioactivity
in comparison to SARTANs may be attributed mainly to two reasons:
ﬁrst, although it resides at the interface regime of lipid bilayers in
the same manner as SARTANs do, its thermodynamical and
structural effects are not as pronounced. This may preclude MMK3
to reach the critical concentration for reaching the active site of the
receptor. Second, although the drug molecule ﬁts nicely to the active
site of the receptor, it does not exert the right interactions with the
key amino acids lacking the proper stereoelectronic requirements.
Therefore, MMK3's Odyssey to Ithaca is restrained by two elements:
the nature of the bilayer matrix and stereoelectronic active site
requirements.
To further examine the role of the lipid bilayers we are currently
performing similar studies with other AT1 antagonists. Hitherto, such
studies show that AT1 antagonists do not exert a unique perturbing
effect, and hence, these results urge for more comprehending
understanding of the role of lipid bilayers in the antihypertensive
drug action.In this respect, we like to point out that there is a growing
awareness that even small structural variations in the composition of
cell membranes can inﬂuence the function of intrinsic membrane
proteins. Any membrane active drug does change the lateral pressure
proﬁle in bilayers and hence, can affect the behavior of membrane
proteins [73]. This means that at least locally any membrane interface
active solute leaves its special ﬁngerprint [74], and it will be of great
importance for future rational drug design to understand not only
direct drug action at the active site, but also to understand speciﬁc
drug to bilayer interactions to foresee at least qualitatively the
consequences for drug efﬁciency.
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